Conditions: Congenital Bleeding Disorder Haemophilia A With Inhibitors Haemophilia B With Inhibitors
Allocation: RANDOMIZED | Intervention model: CROSSOVER
Enrollment: 72
Healthy volunteers: no

Brief summary:
This trial is conducted globally. The purpose of this trial is to confirm the efficacy and safety of NNC 0078-0000-0007 in patients with congenital haemophilia and inhibitors.

Detailed description:
Scheduled dose visit in a non-bleeding state. Single dose of NNC 0078-0000-0007 (vatreptocog alfa (activated)) every 3 months.

Arms:
arm 1: None arm 2: None

Interventions: intervention 1: vatreptacog alfa (activated) intervention 2: eptacog alfa (activated)
Intervention descriptions: intervention 1: 1-3 doses per bleeding episode intervention 2: 1-3 doses per bleeding episode

Protocol document: